GEN-MKT-18-7897-A
May 18, 2020 | Biopharma, Blogs | 0 comments
Comprehensive characterization of a biologic requires analysis at both the intact and digest levels, but these analyses can be complex and cumbersome. For example, with conventional liquid chromatography separations, researchers are often left with limited information due to problems with either very small or very large protein and peptide retention. Unfortunately, slow going methods like these do not mesh with the rapid onset of novel drug approvals and researchers are left wanting more. As in, a more reliable and comprehensive process for characterizing biologics to move them through the drug development pipeline, without compromising on results.Download the Latest Biologics Research >
Go with the CESI-MS FlowThe good news is there are alternatives to existing workflows. For example, using CESI coupled with mass spectrometers (CESI-MS), researchers gain a more comprehensive biologic outlook while at the same time saving almost a day’s worth of time in the lab. Intrigued? We’ve put together in an online eBook that provides vivid illustrations, application notes, and video demonstrations for a solid multi-level characterization biologic foundation, and it’s all here for the taking. This is not your typical brochure, but rather a self-guided tour to be shared with your co-workers as they ask questions and get immediate answers to their most pressing characterization questions. Discover ways to advance your biologics characterization studies using instrumentation like the CESI 8000 Plus coupled with a TripleTOF® mass spectrometer. Together, they give you high-resolution separations with the unique detection capabilities and dedicated software designed for biologics analysis. From intact analysis to peptide mapping, get an inside look at how CESI-MS can advance your investigations of glycosylation, a drug to antibody ratio (DAR), disulfide bond mapping, and PTM identification. Go inside the lab and see the instrument at work using single injection technology for multi-level characterization of a biotherapeutic. Alternatively, view a video showing how powerful software solutions can help you to simplify your comparability work– all in this feature-rich online guide. It’s an interactive tour that gives you all the insight you need for linking CESI technology to high-performance mass spec.
As therapeutic pipelines continue to diversify, bioanalysis is being asked to do more than ever before. From small molecules to complex biologics, today’s scientists must generate high‑quality, reliable data across a growing range of molecule types and workflows, often under increasing time pressure.
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
Posted by
You must be logged in to post a comment.
Share this post with your network